

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3860)

DISPOSAL OF SHARES BY CONTROLLING SHAREHOLDER

This announcement is made by EPS Creative Health Technology Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company has been informed by EPS Holdings, Inc. (“**EPS HD**”), a controlling shareholder of the Company (as defined in the Listing Rules) that, on 9 September 2026, EPS HD entered into an agreement (the “**Sale and Purchase Agreement**”) with Wisdoms Group International Co., Limited (“**Wisdoms Group**”) for the disposal (the “**Disposal**”) of up to 130,000,000 ordinary shares of the Company (the “**Shares**”), representing 22.32% of the issued share capital of the Company, at HK\$0.63 per Share. Completion of the Disposal is expected to take place in two tranches, with the first tranche involving 74,500,000 Shares to be completed on or before 31 December 2026 (the “**Tranche A Completion**”) and the second tranche involving up to 55,500,000 Shares to be completed on or before 31 December 2027, each subject to the fulfilment of certain conditions precedent (including but not limited to any lender’s consent, approval or waiver under any financing arrangement of EPS HD or its ultimate beneficial owner(s)) set out in the Sale and Purchase Agreement. Wisdoms Group has undertaken in the Sale and Purchase Agreement to procure the purchase of up to 30,000,000 Shares by certain prospective purchasers approved by EPS HD, each of whom shall be a director, senior management, consultant or employee of EPS HD and its subsidiaries (including the Company), within thirty (30) days after the Tranche A Completion.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, as at the date of this announcement, (i) Wisdoms Group is a company incorporated in Hong Kong with limited liability which is principally engaged in the provision of consulting service and investment holding and is wholly and beneficially owned by Kaku Ken; and (ii) Precision Medicine Investment & Development Liability Partnership, in which Kaku Ken is a limited partner, is

interested in 20,594,249 Shares, representing approximately 3.54% of the issued share capital of the Company. Wisdoms Group and its ultimate beneficial owner are third parties independent of the Company and its connected persons (as defined in the Listing Rules).

Kaku Ken had previously served as a consultant of EPS HD. He is also a partner of AIS Capital Partners Limited Liability Partnership, the general partner of BooSTARX Fund No. 1 Limited Partnership* (“**BooSTARX**”). The Group had committed to invest JPY100 million (equivalent to approximately HK\$7.1 million) in BooSTARX as a limited partner as disclosed in the announcement of the Company dated 30 August 2021, but such investment was disposed of by the Group to EPS HD in March 2025. Save as disclosed, there is no past or present business or other relationship between Wisdoms Group, its ultimate beneficial owner, Kaku Ken, and the Group.

Upon completion of the Disposal in full, EPS HD will remain as the single largest shareholder and a controlling shareholder of the Company (as defined in the Listing Rules) holding not less than 245,000,000 Shares, representing approximately 42.07% of the issued share capital of the Company.

As a result of the Disposal, the Board expects there will be potential changes to the composition of the Board and the management of the Group, but the Group’s business strategy and development direction are expected to remain unchanged notwithstanding the Disposal. The Board does not expect that the Disposal will have any material adverse impact on the business operations of the Group. Further announcement will be made by the Company regarding the changes to the composition of the Board as and when appropriate in accordance with the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
EPS Creative Health Technology Group Limited
Miyano Tsumoru
Executive Director

Hong Kong, 9 September 2026

As at the date of this announcement, the executive Directors are Mr. Washikita Kenichiro, Mr. Miyano Tsumoru, Mr. Narumi Shoichi, Ms. Du Yao, Mr. Liang Fei and Mr. Kitagawa Rikiya; the non-executive Director is Mr. Uematsu Takahiro; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Choi Koon Ming, Mr. Saito Hironobu and Ms. Zhang Cuiping.

* *For identification purpose only*